Newsletter | April 2, 2020

04.02.20 -- Biosimilars In The Age Of Covid-19

Featured Editorial
Biosimilars In The Pandemic Age: Current Impact And Market Implications
By Anna Rose Welch, editor, Biosimilar Development

This has been a very exciting time for those in drug discovery, while it’s been a bit quieter on the biosimilar front (understandably). That said, there have been a few tidbits of knowledge here and there about the impact this pandemic may or may not yet be having on the biosimilar space.

Shifting Site Of Care For Infused Drugs: An Opportunity For Biosimilars
By Jeremy Schafer, Precision for Value

Site of care strategies can generate cost savings, but they may also create unintended consequences as new controls disrupt the traditional dynamics of buy and bill. However, just as biosimilars have disrupted the status quo of the biologics market, they may also find opportunity in impacting how care is delivered.

Industry Insights
The Importance Of In Vitro Assays For The Development Of Biosimilars
Podcast | By Amanda Turner, Bio-Rad Laboratories, Inc.

Biosimilar expert Amanda Turner provides an overview of the factors that are important when considering which assays and antibodies to utilize in biosimilar development.

6 Reasons You Don’t Use Pharmaceutical Market Research
Article | ISR Reports

If you're using one of these six excuses for ignoring pharma market research, you're failing to understand barriers to success, missing the market’s perspective, and leaving assumptions unvalidated.

Expanding SPR Uses In Antibody Effector Function Determination
Webinar | GE Healthcare Life Sciences

Surface plasmon resonance (SPR) can be implemented at early stages in screening and testing strategies in order to provide better, faster, and stronger analysis of drug candidates. In order to minimize risk and to get “true” affinity in binding analysis, we have adopted the latest innovation in SPR technology, Biacore™ 8K, to develop and qualify assays for monoclonal antibodies and other therapeutic proteins to ensure all critical quality attributes are set and controlled with accuracy and precision.

  DIA 2020 Global Annual Meeting

We are thrilled to offer top-tier content and share global thought leadership in one customizable program at the DIA 2020 Global Annual Meeting. DIA 2020 is more than a meeting: It’s fueled by our common goal to bring life-saving medicines to patients. DIA 2020 consists of 250+ sessions woven through 13 unique tracks with nine different learning formats, ensuring all have the best learning experience.

Connect With Biosimilar Development: